Targeted therapy drugs like vascular endothelial growth factor (VEGFA) inhibitor bevacizumab, epidermal growth factor receptor (EGFR) inhibitor cetuximab and panitumumab have been granted by Food and Drug Administration (FDA) for metastasis CRC treatment [60, 61]. This evidence concerns the gene VEGFA and colorectal carcinoma.